ARTICLE | Company News
Cambridge NeuroScience other research news
July 17, 2000 7:00 AM UTC
CNSI received a $100,000 Phase I SBIR grant from the National Institute of Neurological Disorders and Stroke to develop its Neuregulin-2 as a nervous system disorder treatment. CNSI, which is being ac...